KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Eli Lilly (LLY) over the last 16 years, with Q4 2025 value amounting to -$100000.0.

  • Eli Lilly's Long-Term Debt Repayments rose 5000.0% to -$100000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$300000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $778.0 million for FY2025, which is 1716.87% up from last year.
  • Eli Lilly's Long-Term Debt Repayments amounted to -$100000.0 in Q4 2025, which was up 5000.0% from -$200000.0 recorded in Q4 2024.
  • Over the past 5 years, Eli Lilly's Long-Term Debt Repayments peaked at $1.9 billion during Q3 2021, and registered a low of -$200000.0 during Q4 2024.
  • For the 4-year period, Eli Lilly's Long-Term Debt Repayments averaged around $577.5 million, with its median value being $355.1 million (2021).
  • Per our database at Business Quant, Eli Lilly's Long-Term Debt Repayments plummeted by 5000.0% in 2021 and then skyrocketed by 5000.0% in 2025.
  • Eli Lilly's Long-Term Debt Repayments (Quarter) stood at $100000.0 in 2021, then surged by 849800.0% to $849.9 million in 2022, then tumbled by 100.02% to -$200000.0 in 2024, then skyrocketed by 50.0% to -$100000.0 in 2025.
  • Its Long-Term Debt Repayments stands at -$100000.0 for Q4 2025, versus -$200000.0 for Q4 2024 and $849.9 million for Q2 2022.